読み込み中
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
終値時点
$2.45
−$0.05 · -2.00%
時間外
$2.45
$0.00 · 0.00%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
日中レンジ
現在 $2.45
52週レンジ
現在 $2.45
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
23
割高
センチメント
43
まちまち
リスク
72
高リスク
モメンタム
27
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
日中レンジ
現在 $2.45
52週レンジ
現在 $2.45
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CHF） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 357.3万 CHF | 2730.9万 CHF | 1480.1万 CHF | 393.5万 CHF | — |
| 売上原価 | — | 6257万 CHF | 5460.6万 CHF | — | — |
| 粗利益 | 357.3万 CHF | −3526.1万 CHF | −3980.5万 CHF | 393.5万 CHF | — |
| 研究開発 | 5643.6万 CHF | 6257万 CHF | 5460.6万 CHF | 6033.6万 CHF | 6228.2万 CHF |
| 販売・一般管理 | 1165.2万 CHF | 1143.4万 CHF | 1057.6万 CHF | 958.2万 CHF | 1087.9万 CHF |
| 営業費用 | 7243.6万 CHF | 1711.7万 CHF | 1381.9万 CHF | 7478.2万 CHF | 7901万 CHF |
| 受取利息 | 186.5万 CHF | 319.6万 CHF | 104.4万 CHF | 6.9万 CHF | 648.5万 CHF |
| 支払利息 | 19.1万 CHF | 13.3万 CHF | 17.6万 CHF | 35.5万 CHF | 58.1万 CHF |
| 減価償却費と償却費 | 250.3万 CHF | 216.2万 CHF | 221.5万 CHF | 235.9万 CHF | 240.6万 CHF |
| 営業利益 | −6886.3万 CHF | −5237.8万 CHF | −5362.4万 CHF | −7084.7万 CHF | −7901万 CHF |
| 純利益 | −7044.7万 CHF | −5091.6万 CHF | −5423.3万 CHF | −7075.3万 CHF | −7299.6万 CHF |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.33
上昇余地（240.00%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Biotechnology ETFIBB118.98万0.01%108.2億 USD0.44%$204.26-1.08%
Dimensional - US Small Cap ETFDFAS31.53万0.00%338.69億 USD0.31%$78.17-0.23%
U.S. Micro Cap Portfolio ETFDFMC11.02万0.00%75.58億 USD0.43%$57.70-0.20%
U.S. Vector Equity Portfolio ETF Class SharesDXUV3.96万0.00%61.81億 USD0.26%$68.32+0.06%
Dimensional - US Core Equity 2 ETFDFAC1.97万0.00%885.96億 USD0.21%$45.31-0.04%
Invesco Nasdaq Biotechnology ETFIBBQ1.89万0.02%1.12億 USD0.19%$34.2482-1.07%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.44万0.00%455.91億 USD0.17%$84.43-0.01%
ProShares Ultra Nasdaq BiotechnologyBIB97750.01%9320.36万 USD1.19%$108.79-1.90%iShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACInvesco Nasdaq Biotechnology ETFIBBQU.S. Core Equity 1 Portfolio ETF Class SharesDCORProShares Ultra Nasdaq BiotechnologyBIBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
